Researchers provide evidence linking 'leaky gut' to chronic inflammation

April 20, 2017

With the help of genetically engineered mice, scientists at the Massachusetts General Hospital (MGH) are moving closer to establishing the role that increased intestinal permeability, sometimes called a "leaky gut," plays in chronic inflammatory conditions. Regulated by a protein called zonulin, elevated intestinal permeability has been associated with several chronic conditions including autoimmunity, metabolic disorders, neurodegenerative diseases and even cancer.

In an article published in Annals of the New York Academy of Sciences, lead author Craig Sturgeon, a graduate student in the Mucosal Immunology and Biology Research Center (MIBRC) at MGH, and colleagues provide a direct link between increased of the small intestine and chronic inflammatory disease. They describe how inducing colitis in with two copies of the zonulin-producing gene variant led to significantly more severe symptoms and increased mortality compared with inducing colitis in animals without the zonulin gene.

"This is the first time that we have been able to mechanistically link zonulin-dependent modulation of small-intestinal permeability and the resulting enhanced antigen trafficking to the development of an inflammatory disease," says Alessio Fasano, MD, director of the MIBRC and senior author of the article. "When we exposed these two groups of to inflammatory stress, the zonulin transgenic mice showed a remarkable increase in colon inflammation and in mortality—up to 70 percent—compared to normal mice."

In a related finding that Fasano calls "even more remarkable," adding a zonulin inhibitor—AT1001, also called larazotide acetate—to the drinking water of the transgenic mice completely protected the animals from colonic inflammation and death, reducing permeability of the small intestine to normal levels, despite continued zonulin expression.

Fasano's group discovered zonulin, which controls the opening of "tight junctions" between cells lining the digestive tract, in 2000. Since then it has been the subject of numerous studies implicating intestinal permeability in . In 2001 while at the University of Maryland School of Medicine, Fasano developed AT1001 as a therapeutic agent for celiac disease. The zonulin-blocking agent is set to undergo Phase III clinical trials later this year, according to Innovate BioPharmaceuticals, which has licensed development of the drug from Alba Therapeutics, a company co-founded by Fasano.

A professor of Pediatrics at Harvard Medical School, Fasano explains that, while some alternative health care practitioners use the term "leaky gut syndrome" to describe a variety of health problems ranging from gastrointestinal complaints to neurological symptoms, he prefers the concept of loss of intestinal barrier function. "Leaky gut syndrome has been blamed by some non-mainstream practitioners as the reason for almost everything that is wrong with a person. With the development of this mouse model to study inflammation, we'll be able to separate science from speculation," he says.

Lead author Sturgeon adds, "Use of these mice will allow us to gain insight into specific mechanisms by which zonulin-dependent increased can affect disease onset, clinical severity and outcomes, and even possible prevention." Jinggang Lan, PhD, of the MIBRC is also a co-author of the Annals of the New York Academy of Science paper. The study was supported by National Institutes of Health grant DK048373.

Explore further: Research finds new link between zonulin and two common inflammatory bowel conditions

More information: Craig Sturgeon et al, Zonulin transgenic mice show altered gut permeability and increased morbidity/mortality in the DSS colitis model, Annals of the New York Academy of Sciences (2017). DOI: 10.1111/nyas.13343

Related Stories

Research finds new link between zonulin and two common inflammatory bowel conditions

October 27, 2015
The intriguing story of the recently-discovered protein, zonulin, advances a chapter today as Italian scientists announce the results of their latest research linking zonulin with two common inflammatory bowel conditions. ...

Study identifies a genetic link to susceptibility and resistance to inflammatory bowel disease

April 13, 2017
Inflammatory bowel disease (IBD), characterized by chronic relapsing inflammation of the gut, is a common problem in the industrialized world. However, how IBD develops remains unknown. There is currently no cure and treatment ...

Changes in blood-brain barrier, intestinal permeability found in individuals with autism

January 18, 2017
Autism spectrum disorder (ASD) has the dubious distinction of being the fastest-growing developmental disability in the U.S., according to the Centers for Disease Control and Prevention. With 1 in every 68 children born in ...

Cytokine controls immune cells that trigger inflammatory bowel disease, study finds

April 18, 2017
A certain cytokine, or small protein that helps cells communicate during immune responses, can control whether immune cells promote or suppress inflammatory bowel disease, a finding that could lead to new treatments, according ...

Gut microbes contribute to age-associated inflammation, mouse study finds

April 12, 2017
Inflammation increases with age and is a strong risk factor for death in the elderly, but the underlying cause has not been clear. A study published April 12 in Cell Host & Microbe reveals that gut microbes are one of the ...

Recommended for you

Evidence found of oral bacteria contributing to bowel disorders

October 20, 2017
(Medical Xpress)—An international team of researchers has found evidence that suggests certain types of oral bacteria may cause or exacerbate bowel disorders. In their paper published in the journal Science, the group describes ...

New compound discovered in fight against inflammatory disease

September 22, 2017
A 10-year study by University of Manchester scientists for a new chemical compound that is able to block a key component in inflammatory illness has ended in success.

Asthma researchers test substance from coralberry leaves

September 14, 2017
The coralberry could offer new hope for asthmatics. Researchers at the University of Bonn have extracted an active pharmaceutical ingredient from its leaves to combat asthma, a widespread respiratory disease. In mice, it ...

Respiratory experts urge rethink of 'outdated' asthma categorisation

September 12, 2017
A group of respiratory medicine experts have called for an overhaul of how asthma and other airways diseases are categorised and treated.

New 'biologic' drug may help severe asthma

September 7, 2017
(HealthDay)—A "biologic" drug in development to treat severe asthma reduces the rate of serious attacks by about two-thirds compared to a placebo drug, according to preliminary research findings.

Songbird study shows how estrogen may stop infection-induced brain inflammation

August 31, 2017
The chemical best-known as a female reproductive hormone—estrogen—could help fight off neurodegenerative conditions and diseases in the future. Now, new research by American University neuroscience Professor Colin Saldanha ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.